New video and poster:
As the field of advanced therapies matures, the need for adaptable and scalable platform solutions becomes increasingly paramount to drive down costs and democratize access for patients. In this thought leadership piece, our experts will describe key learnings to leverage for the integration of cutting-edge technologies and optimization of unit operations with the goal of propelling the development and manufacturing of your advanced therapies.
From plasmid production to viral vector manufacturing to cell therapy processing analytics supporting each of these services, SK pharmteco’s experts and innovators discuss the challenges and solutions for robust platforms for cell and gene therapies.
In this engaging 10-minute video, our experts are delving into the innovative strategies and transformative potential of employing a platform approach to advance therapies swiftly from concept to clinical application. Learn more about:
- Considerations underpinning robust platform design tailored for the unique challenges of cell and gene therapies;
- Exploration of key features and integrations to enhance process and production efficiency;
- Recommendation for end-to-end offering for plasmid production, viral vector manufacturing, cell therapy processing, and in-process and release analytics.
If you prefer to read rather than watch, our poster presentation on “Accelerate Time to Clinic for Advanced Therapies with a Platform Approach” provides a comprehensive overview of the topic. Click below to download!
Any questions about the video or the poster? Click here to ask it to our experts! They will get back to you ASAP.
About the speakers:
John Lee, Ph.D., Global Head of Cell and Gene Therapy.
Dr. Lee is an accomplished CAR-T immunobiologist with over 20 years of cancer cell biology expertise spanning small and large molecules, as well as cell-based therapeutics. He possesses more than 15 years of clinical research and cell therapy experience including positions at The Wistar Institute, Janssen Pharmaceuticals, and GlaxoSmithKline. Dr. Lee previously built the Cell Therapy Platform team at Janssen Pharmaceuticals. The group led and supported end-to-end therapy discovery and development across nearly a dozen CAR-T programs, including the recently approved cilta-cel (Carvykti). During his subsequent tenure as Vice President, Head of Oncology Cell Therapy at GlaxoSmithKline, Dr. Lee’s team operated within a heavily matrixed organization to support an array of activities establishing multiple preclinical assets and several clinical-stage lete-cel programs targeting the NY-ESO cancer-testis antigen. Dr. Lee holds a Ph.D from the Brody School of Medicine, an MBA from Penn State University, and a Bachelors of Science from Indiana University of Pennsylvania.
Dana Cipriano, Global Head of Testing and Analytical Services.
Dana has over a 20-year career in biotechnology and cell and gene therapy with leadership roles in Laboratory Operations and Project Management, with focus on designing processes and testing programs to drive sustainable growth and profitability. She was most recently Senior Director of Testing Operations and Strategic Projects for WuXi Advanced Therapies where she directed testing operations for cell and gene therapy and biologics testing, including characterization, release, safety, and viral clearance testing for clinical and commercial products. She also helped create the overall testing business strategy, drove tactical implementation plans, and monitored key milestones to drive delivery of strategic objectives. Dana developed a fully-integrated program for development of a new corporate strategy centered on driving scalability in cell and gene therapy testing services, including design and construction of a new cGMP testing facility. Dana has a Masters in Microbiology from Thomas Jefferson University, a Bachelor’s in Biology from Rutgers University, an Executive Education Certification from The Wharton School, and a PMP (Project Management Professional) certification.
Cédrick Rousseaux, Innovation, Analytical, and Process Development Director.
Cédrick Rousseaux held several positions in Tech transfer and Process Development since he joined the company in 2015. Cédrick has worked in the medical device field for more than 15 years before joining SK pharmteco and held several jobs in cGMP manufacturing as well as in analytical or process tech transfer. Cedrick holds a Cellular and Molecular Engineering master’s degree from Lille University.
